Some cancer treatments reduce saliva: radioactive iodine, lutetium-177 PSMA therapy and some tablets. Sips of water, sugar-free gum and saliva sprays or gels can ease it, and less saliva means more tooth decay, so dental care matters. Tell your team if it is hard to eat or talk, or your mouth is sore or has white patches. Your own team's advice comes first.
This page covers dry mouth from radioactive iodine (I-131), PSMA radioligand therapy, futibatinib and selpercatinib. It is for understanding care; the treating team's own protocol comes first. Frequency, from the labels: lutetium-177 vipivotide tetraxetan 46% in the pooled US safety population (N = 1320; 61% in PSMAfore, 39% in VISION) and 39.3% in the EU SmPC (VISION); futibatinib 35% (US label, 103 patients, no grade 3) and 31.0% (EU SmPC); selpercatinib 44%, 39% and 32% across LIBRETTO-001, -431 and -531 (US label), very common in the EU SmPC. The US sodium iodide I 131 label lists sialadenitis and xerostomia as radiation toxicities; the ATA (2025) cites acute salivary side effects in 39% of 262 patients in the first year after ablation.
Prevention. For radioiodine the ATA recommends counselling and general measures including hydration (both Good Practice Statements) and calls the role of sour sweets and other sialagogues uncertain, with evidence insufficient to recommend for or against hydration, sour candies, amifostine or cholinergic agents as gland protection. The US label, by contrast, advises good hydration for one week and a sialagogue. A 2026 systematic review of sialagogue timing (three observational studies, 818 adults) could make no definitive recommendation. For lutetium-177 PSMA therapy the EANM/SNMMI guideline (2023) gives no general recommendation on drugs to reduce salivary uptake; a full-text review and the one ice-pack study read found cooling of limited or doubtful value.
Dose rules. Only lutetium-177 vipivotide tetraxetan has a dry mouth rule, and the labels differ: the US label withholds at grade 2 or 3 and stops for good if grade 3 recurs after one reduction; the EU SmPC lists a 20% reduction at grade 3 only. Futibatinib and selpercatinib fall under each label's general rule for other grade 3 or 4 reactions.
Relief. The ISOO/MASCC/ASCO guideline (2021) says topical lubricants or saliva substitutes may be offered for xerostomia from nonsurgical cancer therapies (evidence quality intermediate, strength strong), and sugar-free lozenges or gum (intermediate, moderate). Its pilocarpine and cevimeline recommendation is for dry mouth after head and neck radiotherapy only. For PSMA therapy the EANM/SNMMI guideline says pilocarpine must be weighed for the individual because benefits and risks could be closely balanced, and that sialendoscopy may help unacceptable xerostomia (weak). The MASCC/ISOO statement (2024, expert opinion) adds a medicines review, dental care two to four times a year, fluoride, and antifungal treatment for clinical oral candidiasis. No guideline read addresses dry mouth from kinase inhibitors, or from actinium-225 PSMA agents, which are investigational.
Why: The ATA explains that salivary gland cells take up iodine, and that swelling, pain and dryness of the mouth can occur in the weeks after treatment. It says that, rarely, the effects become chronic and severe, with dry mouth, more tooth decay and interference with taste.
“Patients should be counseled that RAI treatment may be associated with (acute and chronic) salivary gland morbidity, lacrimal duct stenosis, and potential risk of secondary malignancies.”
Thyroid (Ringel et al.); funded by the American Thyroid Association without commercial support 2025 · Good Practice Statement
Why: The labels give the figures. Lutetium-177 vipivotide tetraxetan: 46% in the pooled US safety population and 39.3% in the EU SmPC. Futibatinib: 35% in the US label and 31.0% in the EU SmPC, with no grade 3 dry mouth in the US table. Selpercatinib: 44%, 39% and 32% in the three studies in the US label; the EU SmPC lists it as very common. The US label for lutetium-177 vipivotide tetraxetan has no counselling point on dry mouth; the EU leaflet lists it as a very common side effect.
“The most common (≥20%) adverse reactions were nail toxicity, musculoskeletal pain, constipation, diarrhea, fatigue, dry mouth, alopecia, stomatitis”
Why: The ATA recommends general measures including hydration to prevent salivary side effects. The US label for sodium iodide I 131 advises good hydration for one week after the dose to reduce radiation exposure to the salivary glands. How much to drink is for the treating centre to say.
“For prevention of salivary gland side effects after RAI, general measures including hydration are recommended.”
Thyroid (Ringel et al.); funded by the American Thyroid Association without commercial support 2025 · Good Practice Statement
Why: The US label advises stimulating saliva with a sialagogue, giving sugar-free candy or gum, pilocarpine and ascorbic acid as examples. The ATA says some centres suggest sour lozenges and other groups consider them harmful, cites one study in which sour candy within one hour of treatment may have increased gland damage compared with starting 24 hours later, and finds the evidence insufficient to recommend for or against them. A 2026 systematic review of three observational studies found the evidence on timing inconsistent.
“Hence, the role of sour candies to increase salivary secretion after RAI is uncertain.”
Thyroid (Ringel et al.); funded by the American Thyroid Association without commercial support 2025
Why: The ATA says most people with this radiation sialadenitis respond well to non-steroidal anti-inflammatory drugs, that a short course of steroids is occasionally required for severe symptoms, and that local application of ice may relieve the pain. These are statements in the guideline's text, not graded recommendations.
“For salivary gland pain and swelling (radiation-induced sialadenitis), most patients respond well to nonsteroidal anti-inflammatory drugs, but occasionally a short course of steroids is required for severe symptoms.”
Thyroid (Ringel et al.); funded by the American Thyroid Association without commercial support 2025
Why: The EANM/SNMMI guideline says no general recommendation can be given on drug interventions, and warns that they may also change the uptake ratios used to select patients. It does not mention cooling or botulinum toxin; the 2022 review names botulinum toxin as a possible method that warrants further studies. The one ice-pack study read (PSMA PET scans, not treatment) concluded that ice packs in lutetium-177 PSMA therapy should remain optional and most likely do not reduce dry mouth, and a 2022 review concluded that external cooling has shown a limited role with temporary effects.
“Several drug interventions (e.g., oral glutamate, atropine injections, pre-dosing with unlabeled PSMA ligands) to reduce off-target uptake of PSMA ligands in salivary glands or kidneys have been suggested [103]. Due to the limited evidence available, at this point, no general recommendation can be given.”
Why: Both labels grade by the most current CTCAE. In CTCAE version 6.0, grade 2 is moderate symptoms with changes to oral intake such as copious water, other lubricants or a diet limited to purees or soft, moist foods, and grade 3 is being unable to take adequate food by mouth, so that tube feeding or intravenous nutrition is indicated. The reduced dose is 5.9 GBq (5 900 MBq in the EU text). Both texts say the dose may be reduced once and should not be raised again. If a delay for an adverse reaction lasts more than 4 weeks, the US label says to consider stopping for good and the EU SmPC says treatment must be discontinued.
“Grade 2 Withhold PLUVICTO until improvement or return to baseline. Consider reducing PLUVICTO dose by 20% to 5.9 GBq (160 mCi). Grade 3 Withhold PLUVICTO until improvement or return to baseline. Reduce PLUVICTO dose by 20% to 5.9 GBq (160 mCi). Recurrent Grade 3 dry mouth after one dose reduction Permanently discontinue PLUVICTO.”
Novartis, via DailyMed (US National Library of Medicine) 2026
Why: Neither label has a rule written for dry mouth. For futibatinib the US label and the EU SmPC say the same: withhold for grade 3 until it resolves to grade 1 or baseline, resume at the next lower dose, and stop for good for grade 4. For selpercatinib the US label withholds for grade 3 or 4 until recovery to baseline or grade 0 or 1 and resumes at a reduced dose; the EU SmPC suspends until recovery to baseline, resumes at a reduced dose, and discontinues permanently if grade 4 events recur after dose modification.
“Withhold LYTGOBI until toxicity resolves to Grade 1 or baseline, then resume LYTGOBI”
Why: This recommendation is worded for dry mouth from nonsurgical cancer therapies, although the four trials the guideline describes for it were in people who had radiotherapy. For lutetium-177 PSMA therapy the EANM/SNMMI guideline says mild dry mouth can be alleviated with water, sprays of artificial saliva or xylitol lozenges. The MASCC/ISOO statement says products containing mucin are generally preferred over those containing carboxymethylcellulose, and that the relief is short-lived.
“Topical mucosal lubricants or saliva substitutes (agents directed at ameliorating xerostomia and other salivary gland hypofunction-related symptoms) may be offered to improve xerostomia induced by nonsurgical cancer therapies”
Journal of Clinical Oncology (Mercadante et al.); administration funded by MASCC/ISOO and ASCO 2021 · type: evidence-based; evidence quality: intermediate; strength of recommendation: strong
Why: This recommendation names no treatment; the one trial of gum the guideline describes was after radiotherapy for head and neck cancer. The guideline says these give a temporary rise in saliva and temporary relief by stimulating whatever gland tissue still works, and that sugar-free matters because less saliva raises the risk of tooth decay. The NHS tells people with their own teeth not to use acidic artificial saliva products. In the first day after radioactive iodine, whether to stimulate saliva at all is unsettled (see the step on sour sweets).
“sugar-free lozenges, acidic (nonerosive and sugar-free special preparation if dentate patients) candies, or sugar-free, nonacidic chewing gum may be offered to produce transitory increased saliva”
Journal of Clinical Oncology (Mercadante et al.); administration funded by MASCC/ISOO and ASCO 2021 · type: evidence-based; evidence quality: intermediate; strength of recommendation: moderate
Why: This is what Macmillan, the NHS and the NCI tell patients. The NCI says to drink plenty of liquids because a dry mouth can increase the risk of tooth decay and mouth infections; Macmillan says alcohol and smoking can irritate the mouth.
“Take frequent sips of water or a sugar-free drink. Keep a glass of water by your bed and carry a drink with you when you go out.”
Why: The MASCC/ISOO statement says that opioids and anticholinergic medicines are common causes of dry mouth in people with cancer. The NHS tells patients not to stop a prescribed medicine without medical advice.
“If appropriate, a review and adjustment of the patient’s concomitant medications (i.e., number, dosage, formulation) to alleviate salivary gland hypofunction or xerostomia may be explored [4].”
Why: The EANM/SNMMI guideline says this for dry mouth after lutetium-177 PSMA therapy. The ISOO/MASCC/ASCO recommendation for pilocarpine and cevimeline is written only for dry mouth after head and neck radiotherapy. For long-term dry mouth after radioactive iodine the ATA says cholinergic agents may increase saliva, without grading it. No source read addresses these medicines for dry mouth from futibatinib or selpercatinib. The MASCC/ISOO statement lists acute or uncontrolled asthma, acute iritis and narrow angle glaucoma as contraindications, and says a response to pilocarpine may take 12 weeks.
“Due to its own side effects and contra-indications, the use of parasympathomimetics (e.g., the FDA and EMA approved pilocarpine) must consider patient’s individual situation because benefits and risks could be closely balanced [103].”
Why: The MASCC/ISOO statement says people with reduced saliva are at increased risk of tooth decay and should have dental care two to four times a year. The ATA says people with dry mouth after radioactive iodine should discuss preventive strategies with their dental health professional (Good Practice Statement).
“As such, all patients should have regular professional dental care two to four times a year.”
Why: The MASCC/ISOO statement says people with reduced saliva are at risk of opportunistic oral candidiasis. The NHS lists sore white patches in the mouth among the reasons to see a doctor.
“Antifungal therapy should be initiated when there are clinical signs of oral candidiasis, and considered when there are non-specific symptoms suggesting subclinical infection.”
Why: These are the NHS's reasons to see a doctor about a dry mouth, which it files under non-urgent advice. Macmillan adds that someone who coughs when drinking and feels unwell should tell their doctor or nurse as soon as possible. The EU leaflet for lutetium-177 vipivotide tetraxetan asks patients to tell their nuclear medicine doctor if side effects such as dry mouth become severe.
“your mouth is painful, red, swollen or bleeding”
Why: Sialendoscopy passes a fine scope into the salivary duct to wash it out. The EANM/SNMMI guideline says it may improve unacceptable dry mouth after PSMA therapy, on the evidence of a single cohort study, which was in people having actinium-225 PSMA-617. The ATA says several small studies have shown it to be effective for radioiodine sialadenitis that does not respond to medical treatment.
““Unacceptable” xerostomia may eventually be improved by retrograde sialendoscopy and flushing with steroids (weak recommendation based on a single cohort study [102]).”
European Journal of Nuclear Medicine and Molecular Imaging (Kratochwil et al.); several authors declare inventorship of PSMA-617 or consultancy for its manufacturer 2023 · weak recommendation based on a single cohort study
Why: A 2022 meta-analysis of six retrospective studies of actinium-225 PSMA-617 (201 patients) reported dry mouth of any degree in 77.1% and grade III in 3.0%. A 2025 meta-analysis of 20 studies, read as an abstract, pooled any-grade dry mouth at 84% for actinium-225 PSMA given alone, grade 3 at 13%, and stopping treatment because of it at 5%.
Common practice: No guideline or label read covers actinium-225 PSMA agents, so no source states this step. It restates the published rates so that the discussion can happen; the two meta-analyses rest on small and mostly retrospective series.
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
No guideline read was written for dry mouth from kinase inhibitors or from actinium-225 agents, and the guidelines that cover radionuclide therapy rest on low or indirect evidence. What is best supported: counselling before radioactive iodine and general measures including hydration (ATA 2025, both Good Practice Statements); lubricants or saliva substitutes (ISOO/MASCC/ASCO 2021, evidence quality intermediate, strength strong) and sugar-free gum or lozenges (intermediate, moderate), the first worded for xerostomia from nonsurgical cancer therapies and the second naming no treatment, under a clinical question about nonsurgical cancer therapies; dental care and fluoride (MASCC/ISOO 2024, expert opinion; ATA Good Practice Statement). For lutetium-177 vipivotide tetraxetan the dose rule differs by label: the US label withholds at grade 2 or 3 and stops for good if grade 3 recurs after one reduction, the EU SmPC lists a 20% reduction at grade 3 only. The sources disagree on sialagogues after radioactive iodine: the US label advises one, the ATA finds the evidence insufficient to recommend for or against and the role of sour candies uncertain, and a 2026 systematic review could make no definitive recommendation on timing. Pilocarpine and cevimeline carry a strong recommendation only after head and neck radiotherapy; for PSMA therapy the EANM/SNMMI guideline asks for an individual weighing of benefit and risk.
Thyroid (Ringel et al.); funded by the American Thyroid Association without commercial support 2025 · Journal of Clinical Oncology (Mercadante et al.); administration funded by MASCC/ISOO and ASCO 2021 · Supportive Care in Cancer (Hong et al.) 2024 · European Journal of Nuclear Medicine and Molecular Imaging (Kratochwil et al.); several authors declare inventorship of PSMA-617 or consultancy for its manufacturer 2023 · Novartis, via DailyMed (US National Library of Medicine) 2026 · Novartis, via the European Medicines Agency 2026 · Jubilant Radiopharma, via DailyMed (US National Library of Medicine) 2021 · Endocrine 2026
Where it differs: The US label for sodium iodide I 131 (Hicon, revised November 2021) says to advise good hydration for one week and to stimulate salivary flow with a sialagogue, giving sugar-free candy or gum, pilocarpine and ascorbic acid as examples, to reduce radiation exposure to the salivary glands. The ATA (2025) recommends general measures including hydration, and says of hydration, sour candies, amifostine and cholinergic agents as gland protection that the evidence is insufficient to recommend for or against them.
Evidence: The ATA cites one study suggesting sour candy may increase gland damage when given within one hour of treatment compared with starting 24 hours later, a study in which lemon slices within 20 minutes of iodine-123 increased the absorbed dose to the glands, and others suggesting that early and repeated lemon juice transiently decreased exposure of the parotid glands. A 2026 systematic review (three observational studies, 818 adults) found two earlier studies with more acute sialadenitis after early stimulation (54.7 to 63.8% against 34.4 to 36.8%) and a more recent propensity-matched study with fewer events after early stimulation (4.78% against 15.22%), and made no definitive recommendation. A 2022 systematic review of 12 randomised trials (667 participants) found that vitamin C showed no significant effect, that pilocarpine did not protect the parotid glands, and that massage of the parotid gland, aromatherapy, vitamin E, selenium, amifostine and bethanechol may have benefits, in small trials needing confirmation.
Jubilant Radiopharma, via DailyMed (US National Library of Medicine) 2021 · Thyroid (Ringel et al.); funded by the American Thyroid Association without commercial support 2025 · Endocrine 2026 · Frontiers in Endocrinology (Auttara-atthakorn et al.) 2022
Where it differs: US label (SPL effective 12 August 2026): grade 2, withhold until improvement or return to baseline and consider reducing the dose by 20% to 5.9 GBq; grade 3, withhold until improvement or return to baseline and reduce by 20%; recurrent grade 3 after one dose reduction, permanently discontinue. EU SmPC (EMA PDF created 16 June 2026 and modified 16 July 2026): grade 3, reduce the dose by 20% to 5 900 MBq; no entry for grade 2 and no instruction to withhold for dry mouth. Both texts say the dose may be reduced once and should not be re-escalated. For a delay of more than 4 weeks because of an adverse reaction, the US label says to consider permanent discontinuation and the EU SmPC says treatment must be discontinued; the EU SmPC also says it must be discontinued if a further reduction would be required.
Evidence: Regulatory labels, not graded. In the US label dry mouth led to permanent discontinuation in 1.3% of patients in PSMAfore and was the most frequent reaction leading to a dose reduction in PSMAddition (1.1%) and PSMAfore (0.9%). The EANM/SNMMI guideline gives no dose rule specific to dry mouth; it says to discontinue for any toxicity the patient considers unacceptable.
Novartis, via DailyMed (US National Library of Medicine) 2026 · Novartis, via the European Medicines Agency 2026 · European Journal of Nuclear Medicine and Molecular Imaging (Kratochwil et al.); several authors declare inventorship of PSMA-617 or consultancy for its manufacturer 2023
Where it differs: A 2022 review describes frozen ice packs applied on both cheeks from 30 minutes before treatment until up to 4 hours after it, replaced at intervals. The EANM/SNMMI guideline does not mention the practice.
Evidence: A study using PSMA PET scans (not treatment) found that ice packs seemed to reduce tracer uptake in the parotid glands only, and concluded that their routine use in lutetium-177 PSMA therapy should remain optional and most likely does not contribute to a reduction of dry mouth. A 2022 review reported an absolute reduction of about 14% in parotid uptake with a one-sided ice pack in 24 patients and no significant difference with ice packs on both sides in 20, and concluded that external cooling has shown a limited role with temporary effects.
EJNMMI Research (van Kalmthout et al.) 2018 · Translational Oncology (Mahajan et al.); no funding declared 2022 · European Journal of Nuclear Medicine and Molecular Imaging (Kratochwil et al.); several authors declare inventorship of PSMA-617 or consultancy for its manufacturer 2023
Where it differs: The ISOO/MASCC/ASCO recommendation (2.3) is for dry mouth after radiotherapy for head and neck cancer. The EANM/SNMMI guideline and the ATA discuss such medicines after radionuclide therapy without recommending them (see the evidence). The MASCC/ISOO statement gives doses for cancer patients in general: pilocarpine 5 mg, 7.5 mg or 10 mg three to four times a day to a maximum of 30 mg a day, and cevimeline 30 mg three times a day; it says they suit people with some remaining gland function.
Evidence: For PSMA therapy the EANM/SNMMI guideline says the use of pilocarpine must consider the individual because benefits and risks could be closely balanced. For radioactive iodine the ATA says cholinergic agents may increase saliva in chronic dry mouth, ungraded; a 2022 systematic review found pilocarpine did not protect the parotid glands when given to prevent damage. The ISOO/MASCC/ASCO guideline lists sweating, headache, increased urinary frequency, dyspepsia, lacrimation and nausea as expected side effects of pilocarpine, and says cevimeline is available only in selected countries. No source read tested either medicine in dry mouth from kinase inhibitors.
Journal of Clinical Oncology (Mercadante et al.); administration funded by MASCC/ISOO and ASCO 2021 · Supportive Care in Cancer (Hong et al.) 2024 · European Journal of Nuclear Medicine and Molecular Imaging (Kratochwil et al.); several authors declare inventorship of PSMA-617 or consultancy for its manufacturer 2023 · Thyroid (Ringel et al.); funded by the American Thyroid Association without commercial support 2025 · Frontiers in Endocrinology (Auttara-atthakorn et al.) 2022
Where it differs: Not a licensed treatment. The pooled rates of dry mouth below are higher than the figures in the labels for lutetium-177 vipivotide tetraxetan, though they come from retrospective series and not from the same kind of study. Some series give actinium-225 together with lutetium-177 (tandem therapy).
Evidence: Meta-analysis of six retrospective studies of actinium-225 PSMA-617 (201 patients, 2022): dry mouth of any degree in 77.1%, grade III in 3.0%. Meta-analysis of 20 studies (1207 patients, 2025, abstract only): pooled any-grade dry mouth 84% with actinium-225 PSMA alone, grade 3 in 13%, treatment stopped because of it in 5%; a lower pooled rate with tandem therapy, with significant heterogeneity and publication bias. The single cohort study behind the EANM/SNMMI statement on sialendoscopy was in people having actinium-225 PSMA-617.
Frontiers in Oncology (Ma et al.) 2022 · European Journal of Nuclear Medicine and Molecular Imaging (Al-Ibraheem et al.) 2025 · European Journal of Nuclear Medicine and Molecular Imaging (Kratochwil et al.); several authors declare inventorship of PSMA-617 or consultancy for its manufacturer 2023
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Counsel before radioactive iodine about acute and chronic salivary gland morbidity | Good Practice Statement | Thyroid (Ringel et al.); funded by the American Thyroid Association without commercial support 2025 |
| General measures including hydration to prevent salivary side effects after radioactive iodine | Good Practice Statement | Thyroid (Ringel et al.); funded by the American Thyroid Association without commercial support 2025 |
| People with dry mouth after radioactive iodine are at increased risk of tooth decay and should discuss prevention with their dental professional “Patients with xerostomia are at increased risk of dental caries and should discuss preventive strategies with their dental health professional.” | Good Practice Statement | Thyroid (Ringel et al.); funded by the American Thyroid Association without commercial support 2025 |
| Hydration, sour candies, amifostine and cholinergic agents to prevent salivary gland damage from radioactive iodine | evidence is insufficient to recommend for or against (text, not a numbered recommendation) | Thyroid (Ringel et al.); funded by the American Thyroid Association without commercial support 2025 |
| The US label for sodium iodide I 131 advises hydration for one week and a sialagogue “Advise good hydration for one week following sodium iodide I 131 administration and stimulate salivary flow via a sialagogue (e.g. sugar-free candy or gum, pilocarpine, and ascorbic acid) to reduce radiation exposure to the salivary glands.” | Regulatory label; not graded | Jubilant Radiopharma, via DailyMed (US National Library of Medicine) 2021 |
| Topical mucosal lubricants or saliva substitutes may be offered for xerostomia induced by nonsurgical cancer therapies (Recommendation 2.1) | type: evidence-based; evidence quality: intermediate; strength of recommendation: strong | Journal of Clinical Oncology (Mercadante et al.); administration funded by MASCC/ISOO and ASCO 2021 |
| Sugar-free lozenges, acidic candies (non-erosive and sugar-free for people with teeth) or sugar-free, non-acidic gum may be offered (Recommendation 2.2) | type: evidence-based; evidence quality: intermediate; strength of recommendation: moderate | Journal of Clinical Oncology (Mercadante et al.); administration funded by MASCC/ISOO and ASCO 2021 |
| Oral pilocarpine, and cevimeline where available, may be offered after radiotherapy for head and neck cancer (Recommendation 2.3; not written for other treatments) “Oral pilocarpine, and cevimeline where available, may be offered after radiation therapy in patients with head and neck cancer for transitory improvement of xerostomia and salivary gland hypofunction by stimulating residual capacity of salivary gland tissue.” | type: evidence-based; evidence quality: high; strength of recommendation: strong | Journal of Clinical Oncology (Mercadante et al.); administration funded by MASCC/ISOO and ASCO 2021 |
| Most of the ISOO/MASCC/ASCO recommendations focus on radiotherapy for head and neck cancer “majority of the recommendations focus on patients who receive radiation therapy for head and neck cancer.” | Scope statement; not graded | Journal of Clinical Oncology (Mercadante et al.); administration funded by MASCC/ISOO and ASCO 2021 |
| Mild dry mouth after lutetium-177 PSMA therapy: water, artificial saliva sprays or xylitol lozenges “Mild cases of xerostomia can be alleviated with coping water or sprays with artificial salivary supplements or xylitol lozenges; moderate strong recommendation.” | moderate strong recommendation | European Journal of Nuclear Medicine and Molecular Imaging (Kratochwil et al.); several authors declare inventorship of PSMA-617 or consultancy for its manufacturer 2023 |
| Sialendoscopy with steroid flushing for unacceptable dry mouth after PSMA therapy | weak recommendation based on a single cohort study | European Journal of Nuclear Medicine and Molecular Imaging (Kratochwil et al.); several authors declare inventorship of PSMA-617 or consultancy for its manufacturer 2023 |
| Drug interventions to reduce salivary gland uptake of PSMA ligands | no general recommendation can be given | European Journal of Nuclear Medicine and Molecular Imaging (Kratochwil et al.); several authors declare inventorship of PSMA-617 or consultancy for its manufacturer 2023 |
| EU SmPC dose rule for dry mouth on lutetium-177 vipivotide tetraxetan: grade 3 only “Reduce Pluvicto dose by 20% to 5 900 MBq.” | Regulatory label; not graded | Novartis, via the European Medicines Agency 2026 |
| Dry mouth as defined in CTCAE version 6.0, the scale the labels grade by “Definition: A disorder characterized by reduced salivary flow in the oral cavity.” | Grading scale; not a recommendation | US National Cancer Institute 2025 |
| Ice packs during lutetium-177 PSMA therapy “structural application of icepacks in patients undergoing 177Lu-PSMA therapy in advanced prostate cancer should remain optional, but most likely does not contribute to reduction of xerostomia.” | Single study; not graded | EJNMMI Research (van Kalmthout et al.) 2018 |
| Timing of sialagogues after radioactive iodine “Given the scarce and observational nature of available evidence, no definitive recommendation can be made.” | Systematic review of three observational studies; not graded | Endocrine 2026 |
Shares Radiation safety at home after radioactive iodine (I-131) for thyroid cancer, Radiation safety at home after lutetium-177 PSMA or dotatate therapy, Radioiodine therapy (I-131), Radioactive iodine (I-131).
Shares Radioactive iodine (I-131), Radioiodine therapy and whole-body iodine scanning.
Shares Radioactive iodine (I-131), Radioiodine therapy and whole-body iodine scanning.
Shares Radioiodine therapy (I-131), Radioiodine therapy and whole-body iodine scanning.
Shares Radioactive iodine (I-131), Radioiodine therapy and whole-body iodine scanning.
Shares Mouth care and oral mucositis prevention during head and neck radiotherapy, Dry mouth, teeth and taste after head and neck radiotherapy.
Shares Radioactive iodine (I-131), Radioiodine therapy and whole-body iodine scanning.
Shares Mouth care and oral mucositis prevention during head and neck radiotherapy, Oral care and oral mucositis prevention during cancer treatment, Dry mouth, teeth and taste after head and neck radiotherapy.